dermatologyadvisor9h
Positive Results for Tremfya in Low Body Surface Area Psoriasis
Phase 3b trial evaluating Tremfya (guselkumab) in low body surface area plaque psoriasis found the treatment improved clearance.
GlobalData on MSN9h
J&J and Lilly both unveil IL-23 inhibitor efficacy in Crohn’s disease
After both receiving FDA approval in UC, J&J and Eli Lilly are racing for their IL-23 inhibitors to get the green light in ...
Johnson & Johnson's Tremfya Seeks Expanded Use Approval After It Shares Encouraging Late-Stage Study Data In Crohn's Disease
On Monday, Johnson & Johnson (NYSE:JNJ) announced results from the Phase 3 GRAVITI study of Tremfya (guselkumab) for Crohn’s ...
NDTV16h
World News
The United States said Monday it was "deeply concerned" about a bill, now passed by Israel's parliament, that bans the UN's Palestinian refugee agency from operating in the country and occupied ...